Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of motesanib (AMG 706) plus paclitaxel/carboplatin in advanced non-squamous non-small cell lung cancer
2006-003784-32Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing Motesanib + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Overall survival time. Started Mar 2007; status: completed.
02
Drugs
motesanib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2006-003784-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003784-32.